Japanese encephalitis virus vaccine

Japanese encephalitis virus vaccine

(Ja-pan-ees en-se-fa-li-tes vak-seen) ,


(trade name)


Therapeutic: vaccines immunizing agents
Pregnancy Category: B


Active immunization against disease caused by Japanese encephalitis virus (JEV) in persons ≥17 yr.


An inactive form of the virus induces antibodies that neutralize live JEV.

Therapeutic effects

Prevention of disease caused by JEV.


Absorption: Absorption follows intramuscular administration.
Distribution: Unknown.
Metabolism and Excretion: Unknown.
Half-life: Unknown.

Time/action profile (antibody production)

IMunknownwithin 10 daysunknown


Contraindicated in: Serious hypersensitivity to a previous dose; Serious hypersensitivity to protamine.
Use Cautiously in: Immunocompromised patients (may have ↓ response); Obstetric / Lactation: Safety and effectiveness not established; Pediatric: Safety and effectiveness not established.

Adverse Reactions/Side Effects

Central nervous system

  • headache (most frequent)


  • pain (most frequent)
  • tenderness (most frequent)
  • edema
  • pruritus


  • myalgia (most frequent)


Drug-Drug interaction

Concurrent use of immunosuppressives including antineoplastics and corticosteroids may ↓ antibody reponse and ↑ risk of adverse reactions.


Intramuscular (Adults ≥17 yr) 0.5 mL, repeated 28 days later; series completed at least 1 wk prior to potential exposure to JEV.


Suspension for injection (contains protamine): 0.5 mL single dose syringes

Nursing implications

Nursing assessment

  • Determine if patient has had reactions to previous vaccines.
  • Obtain temperature. Vaccine should not be administered to patients with fever >100°F.

Potential Nursing Diagnoses

Risk for infection (Indications)


  • Immunization is administered in 2 doses, 28 days apart, completed at least 1 wk prior to exposure to JEV.
  • Intramuscular: Store in refrigerator; clear liquid with white precipitation may form during storage. Shake syringe well to obtain a white, opaque, homogenous suspension. Do not administer if discolored or contains particulate matter. Inject into deltoid; do not give intravenously, intradermally or subcutaneously.

Patient/Family Teaching

  • Inform patient of the purpose of vaccine and that vaccine is non-infectious. If second dose is missed, contact health care professional to determine when to receive second dose. Maximum protection is not achieved until 1 wk after second dose. Advise patient to read Patient Information Sheet prior to vaccination.
  • Advise patient of precautions to take to reduce exposure to mosquito bites transmitting virus (adequate clothing, use of repellents, mosquito nets). Vaccine may not fully protect everyone who gets the vaccine, does not protect against other types of encephalitis or other diseases transmitted by mosquito bites.
  • Advise patient to tell health care professional what medications they are taking.
  • Advise female patients to notify health care professional if pregnancy is planned or suspected, or if breastfeeding.

Evaluation/Desired Outcomes

  • Protection against Japanese Encephalitis Virus.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
subsidiary of a global biotech company has received Food and Drug Administrationapproval for adramatically shorterdosing regimen for its Japanese encephalitis virus vaccine,allowing patients to protect themselves before travel inless time than previously required.
Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51: six and 12 month results of a multicenter follow-up phase 3 study.
Full browser ?